Metrion and Venomtech Collaborate
Metrion Biosciences Limited (Metrion), the specialist ion channel CRO and drug discovery company, and Venomtech Limited (Venomtech) a biotechnology company with the UK’s largest venom library, today announced a collaboration agreement which will see the two companies combine their resources and expertise to search for novel ion channel modulators for use in drug discovery research.
By combining the expertise and screening capabilities of Metrion with Venomtech’s diverse venom collection, knowledge of venom-based drug discovery, hit prioritisation and bio-guided fractionation capability, this partnership aims to identify, and rapidly exploit, novel tools for ion channel drug discovery research.
Venoms are well proven sources of potent and selective ion channel modulators, and have provided the foundation for many ion channel drug discovery programs to date. Metrion will screen a targeted selection of Venomtech’s venom library against a panel of prioritised ion channel targets to search for, identify and characterise new ion channel modulators and binding sites. Venomtech will use phylogenetic and geographical diversity analysis to design and build a targeted venom discovery array.
Dr Andrew Southan, Head of Commercial Operations at Metrion Biosciences said: “The Metrion team is very pleased to add Venomtech to our network of collaborators. Via this partnership we can rapidly explore the UK’s largest venom collection for novel pharmacological tools for use in ion channel assay development, validation and drug discovery research. The results of this partnership could significantly boost the chances of successful drug discovery against our prioritised ion channel targets, and Metrion is looking forward to a highly productive working relationship.”
Steve Trim, Founder and Managing Director, Venomtech, commented: “This is a fantastic opportunity to combine our knowledge and expertise in venom-based drug discovery with the great team at Metrion and their electrophysiology excellence. This combination of skills is set to solve many of the challenges of getting good drugs for ion channel targets.”
This article has been republished from materials provided by Metrion Biosciences. Note: material may have been edited for length and content. For further information, please contact the cited source.
CRISPR Reveals New Targets for Promising Cancer DrugsNews
Novel screening method identifies new drug targets that could potentially enhance the effectiveness of PD-1 checkpoint inhibitors, a promising new class of cancer immunotherapy.READ MORE
BioAscent Announces New CEO and Plans to Expand Discovery Services OfferingNews
BioAscent Discovery Limited appoints new CEO, Paul Smith in preparation for the expansion of companies discovery services.READ MORE
Cell Recycling System Offers Therapeutic Entry Point for Rare Disease TreatmentNews
Scientists have demonstrated how an investigational drug works against a rare, fatal genetic disease, Niemann-Pick type C1 (NPC1).READ MORE
Comments | 0 ADD COMMENT
EMBL Conference: European Conference of Life Science Funders and Foundations
Apr 19 - Apr 20, 2018